Giovanni Caforio, Bristol Myers Squibb CEO (The Galien Foundation)
October 8, 2023 06:13 PM EDTUpdated October 9, 08:30 AM
Deals

Bris­tol My­ers makes a $4.8B bet on KRAS, strik­ing deal to ac­quire Mi­rati

Lei Lei Wu

News Reporter

Bris­tol My­ers Squibb has signed a $4.8 bil­lion deal to buy Mi­rati Ther­a­peu­tics and its can­cer drug Kraza­ti, which tar­gets what …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

No­var­tis seeks more bolt-on deals as it pur­chas­es neu­ro start­up for up to $1.1B

RFK Jr. and Elon Musk want to ban phar­ma ads. They would­n't be the first to try

Am­gen names Stan­ford ge­neti­cist and biotech founder to CSO post

FDA vac­cine chief Pe­ter Marks pledges to stay as long as he's wel­come

Ky­owa Kirin ac­quires ex-US rights to Ku­ra’s leukemia treat­ment for $330M up­front

sponsored

Are pro­grams with com­pound­ed GLP-1s safe for your pop­u­la­tion?

A service from the Financial Times